^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Cervical Cancer
    Drug:balstilimab (AGEN2034) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Agenus Inc. Press Release
    Title:

    Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer

    Published date:
    06/17/2021
    Excerpt:
    Agenus Inc. (NASDAQ: AGEN)...today announced that the U.S. Food and Drug Administration (FDA) has accepted Agenus’ Biologics License Application (BLA) for balstilimab, an anti-PD-1 antibody, for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The FDA has granted Priority Review to this submission...
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Agenus Inc. Press Release
    Title:

    Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer

    Published date:
    04/07/2020
    Excerpt:
    Agenus Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation for investigation of balstilimab (anti-PD-1) for the treatment of cervical cancer.